ICON (NASDAQ: ICLR), a global provider of outsourced development
services to the pharmaceutical, biotechnology and medical device
industries, today reported its financial results for its second
quarter ended June 30, 2008. Net revenues for the quarter were
$218.3 million, representing a 48.5% increase over net revenues of
$147 million for the comparative quarter last year. Year-to-date,
net revenues were $419.6 million, representing a 48.2% increase
over the same period last year. Income from operations was $24.4
million, compared to $16.1 million for the same quarter last year.
Operating margin increased to 11.2% from 10.9%. Net income was
$18.8 million or 62 cents per share on a diluted basis, compared
with $13.3 million or 45 cents per share last year. Year-to-date
income from operations was $45.9 million, compared to $30.7 million
last year representing a margin of 10.9% in both periods. Net
income was $35.7 million or $1.19 per share, compared with $25.6
million or 86 cents last year. Days sales outstanding were 58 days
at June 30, 2008, compared to 66 days at December 31, 2007. For the
quarter ended June 30, 2008, cash provided by operating activities
was $40.7 million and capital expenditure was $18.9 million. As a
result, the company�s net cash amounted to $6.9 million at June 30,
2008, compared to net debt of $20.2 million at March 31, 2008. �We
are delighted with ICON�s second quarter performance�, commented
Chairman Dr. John Climax. �Revenue growth was very strong and
operating margins showed good progress.� �It was another quarter of
excellent bookings, which were $393 million gross and $337 million
net� said CEO Peter Gray. �As a result of these strong business
wins we continue to expand our global capability through opening
new offices and hiring new staff and we now have in excess of 6500
staff working in 71 offices in 38 countries. The strength of demand
for our global services has led us to increase our revenue guidance
for 2008 to $870 - $890 million, and our EPS guidance to $2.46 -
$2.52.� The company will hold its second quarter conference call
today, July 22, 2008 at 9:00 EST [14:00 Ireland & UK]. This
call and linked slide presentation can be accessed live from our
website at http://www.iconplc.com. A recording will also be
available on the website for 90 days following the call. In
addition, a calendar of company events, including upcoming
conference presentations, is available on our website, under
�Investors�. This calendar will be updated regularly. The
statements made in this Press Release may contain forward-looking
statements that involve a number of risks and uncertainties. In
addition to the matters described in this Press Release, the
ability to maintain large client contracts or enter into new
contracts, maintain client relationships and the ability to manage
the opening of new offices, the integration of new business mergers
and acquisitions, as well as other risks and uncertainties detailed
from time to time in SEC reports filed by ICON, including its Form
20-F, F-1, S-8 and F-3, may affect the actual results achieved by
ICON. ICON disclaims any intent or obligation to update these
forward-looking statements. The financial information presented
herein has been prepared in accordance with U.S. GAAP. ICON plc is
a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The
Company specializes in the strategic development, management and
analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. With
headquarters in Dublin, Ireland, ICON currently,operates from 71
locations in 38 countries and has approximately 6,500 employees.
Further information is available at www.iconplc.com. � � � � � �
ICON plc � Consolidated Income Statements (Unaudited) � Three and
Six Months ended June 30, 2008 and June 30, 2007 (Dollars, in
thousands, except share and per share data) � Three Months Ended
Six Months Ended June 30, June 30, June 30, June 30, 2008 2007 2008
2007 � Gross Revenue 316,592 207,383 600,445 394,123 �
Subcontractor costs 98,292 60,336 180,801 110,987 � � � � Net
Revenue 218,300 147,047 419,644 283,136 � Costs and expenses Direct
costs 122,976 83,875 236,165 162,432 Selling, general and
administrative 64,289 42,662 124,834 81,346 Depreciation and
amortization 6,641 4,450 12,739 8,606 � � � � Total costs and
expenses 193,906 130,987 373,738 252,384 � Income from operations
24,394 16,060 45,906 30,752 � Interest (expense) income (476) 1,019
(519) 2,063 � � � � Income before provision of income taxes 23,918
17,079 45,387 32,815 � Provision for income taxes 4,891 3,758 9,138
7,186 Minority interest 206 6 534 48 � Net income 18,821 13,315
35,715 25,581 � Net income per ordinary share Basic $0.65 $0.46
$1.23 $0.89 � Diluted $0.62 $0.45 $1.19 $0.86 � Weighted average
number of ordinary shares Basic 29,106,694 28,684,201 29,004,662
28,624,350 � Diluted 30,156,563 29,685,489 30,083,989 29,597,671 �
ICON plc � Summary Balance Sheet Data � � June 30, 2008 and
December 31, 2007 (Dollars, in thousands) � June 30, December 31,
2008 2007 (Unaudited) (Audited) Cash and short-term investments
114,389 118,633 Debt (107,400) (94,829) Net cash 6,989 23,804 �
Accounts receivable 221,480 129,865 Unbilled revenue 146,152
144,661 Payments on account (165,218) (96,553) Total 202,414
177,973 � Working Capital 201,862 193,271 � Total Assets 843,968
693,138 � Shareholder's Equity 447,157 388,400 � � Source: ICON plc
� Contact: Investor Relations 1-888-381-7923 or Ciaran Murray CFO+
353 1 291 2000 both at ICON. � http://www.iconplc.com �
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024